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ABSTRACT
Introduction: Heavy menstrual bleeding (HMB)
diminishes individual quality-of-life and poses
substantial societal burden. In HMB endometrium,
inactivation of cortisol (by enzyme 11β hydroxysteroid
dehydrogenase type 2 (11βHSD2)), may cause local
endometrial glucocorticoid deficiency and hence
increased angiogenesis and impaired vasoconstriction.
We propose that ‘rescue’ of luteal phase endometrial
glucocorticoid deficiency could reduce menstrual
bleeding.
Methods and analysis: DexFEM is a double-blind
response-adaptive parallel-group placebo-controlled
trial in women with HMB (108 to be randomised), with
active treatment the potent oral synthetic glucocorticoid
dexamethasone, which is relatively resistant to
11βHSD2 inactivation. Participants will be aged over
18 years, with mean measured menstrual blood loss
(MBL) for two screening cycles ≥50 mL. The primary
outcome is reduction in MBL from screening.
Secondary end points are questionnaire assessments of
treatment effect and acceptability. Treatment will be for
5 days in the mid-luteal phases of three treatment
menstrual cycles. Six doses of low-dose
dexamethasone (ranging from 0.2 to 0.9 mg twice
daily) will be compared with placebo, to ascertain
optimal dose, and whether this has advantage over
placebo. Statistical efficiency is maximised by allowing
randomisation probabilities to ‘adapt’ at five points
during enrolment phase, based on the response data
available so far, to favour doses expected to provide
greatest additional information on the dose–response.
Bayesian Normal Dynamic Linear Modelling, with
baseline MBL included as covariate, will determine
optimal dose (re reduction in MBL). Secondary end
points will be analysed using generalised dynamic linear
models. For each dose for all end points, a 95% credible
interval will be calculated for effect versus placebo.
Ethics and dissemination: Dexamethasone is widely
used and hence well-characterised safety-wise. Ethical
approval has been obtained from Scotland A Research
Ethics Committee (12/SS/0147). Trial findings will be
disseminated via open-access peer-reviewed
publications, conferences, clinical networks, public
lectures, and our websites.
Trial registration number: ClinicalTrials.gov
NCT01769820; EudractCT 2012-003405-98.
INTRODUCTION
Background
Heavy menstrual bleeding (HMB) is deﬁned
as excessive menstrual blood loss that inter-
feres with the woman’s physical, emotional,
social or material quality-of-life.1 The preva-
lence of excessive menstrual bleeding in devel-
oping countries is reported as 4–9%.2
Community surveys of UK menstruating
women have found 35–52% prevalence of
reporting ‘heavy periods’ in the past 6
months,3 4 and 25% annual cumulative inci-
dence of reporting periods as ‘heavy’,4 but
with respect to putative HMB, only 15% who
report both heavy periods and that their
periods are ‘a marked/severe problem’.3
Annually, 1 million UK women seek help for
HMB,1 and an estimated 3.5 million work days
are lost.5 Conservative estimates of annual
direct and indirect economic costs of men-
strual bleeding problems in the USA are US$1
billion and US$12 billion, respectively (in year
2005$).6
Surgical treatments for HMB (hysterectomy,
endometrial ablation) end fertility, and hys-
terectomy is high-cost major surgery. Among
those aged 30–40 years, uterine ﬁbroids are
often the cause of HMB,7 frequently necessi-
tating surgery. In the US 10–15% of women
aged 25–64 have hysterectomy for ﬁbroids8
costing $3 billion annually.6 Hysterectomy
remains a common intervention even in the
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absence of large ﬁbroids.9 It is estimated in England and
Wales, that annually about 80 000 women are referred for
the ﬁrst time to hospital with HMB and approximately
28 000 (35%) undergo surgical treatment.10 A national
4-year audit has reported that in the year following ﬁrst
attendance at hospital for HMB, 43% of women received
surgery (8183 followed up).11 However, given half of all
UK-born babies (47%) are to women aged 30 or older,12
fertility-ending surgery is not always acceptable.
Medical therapy for HMB is either ineffective,10 or asso-
ciated with unacceptable side effects. The Levonorgestrel
intrauterine system (LNG-IUS), a hormonal contracep-
tive now licensed as treatment for HMB, is unsuitable for
women seeking to become pregnant. LNG-IUS can cause
amenorrhoea, or for other users there is ongoing and
unpredictable unscheduled bleeding, and these conse-
quences can be unacceptable to women.13 The audit
reported that in the ﬁrst year after attendance for HMB,
oral medication and IUS were received by 29% and 33%,
respectively, but these were the ‘ﬁnal’ treatment for only
12% (over half switched from oral medication) and 22%
(one third switched from IUS).11 IUS and systemic pro-
gestin therapies for HMB are discontinued by up to one
in ﬁve users due to side effects.14 A recent meta-analysis
concludes that LNG-IUS is less cost-effective than hyster-
ectomy for HMB.15 16
HMB often occurs in combination with other symp-
toms.17 18 The audit 1-year follow-up found only 35% of
women were at least ‘satisﬁed’ at the prospect of current
menstrual symptoms continuing, as currently experi-
enced, for the next 5 years.11 There is therefore unmet
need for cost-effective and acceptable therapy for HMB,
particularly a medical therapy which preserves fertility
and is compatible with becoming pregnant while on
treatment.
Mechanistic rationale for intervention
The cause(s) of HMB are not well understood.
Approximately 48% of cases of HMB referred to second-
ary care occur in the absence of obvious pathology.19 In
the normal menstrual cycle, blood vessel proliferation,
differentiation and vasoconstriction in the endometrium
is tightly regulated to ensure that a controlled and self-
limited endometrial shedding occurs at menses. This is
followed by a self-limiting inﬂammatory response to
endometrial injury to ensure successful healing with a
return to normal architecture, prior to the next cycle of
vascular proliferation.20 These cyclic processes are orche-
strated by dynamic changes in sex steroids and their
interplay with endocrine, vascular and immune systems.
Perimenstrual disturbance in local molecular and cellu-
lar mechanisms that are likely to lead to heavy and/or
prolonged bleeding, include: (1) decreased vasoconstric-
tion; (2) decreased vascular homeostasis; (3) an exces-
sive inﬂammatory response at menses; and (4) defective
repair of the postmenstrual endometrium. Deﬁcient vas-
cular development and abnormal angiogenesis have
been reported in women with HMB.20
Glucocorticoids promote vasoconstriction and inhibit
angiogenesis, so HMB could result from local endomet-
rial glucocorticoid deﬁciency.21–23 We have shown that
endometrium from women with HMB has increased
expression of 11β hydroxysteroid dehydrogenase type 2
(11βHSD2), an enzyme which inactivates the major
endogenous glucocorticoid, cortisol. This may cause
local deﬁciency in endometrial cortisol,21 and result in
an inadequate hypoxic signal at the time of progester-
one withdrawal.20
We propose a novel therapy with synthetic glucocortic-
oid to ‘rescue’ luteal phase endometrial deﬁciency of
cortisol in women with HMB, ensuring endometrial vas-
cular differentiation and inﬂammation are properly con-
trolled during the peri(menstrual) time of the cycle.
There are several potential approaches, including use of
a glucocorticoid receptor (GR) agonist which is less sus-
ceptible than cortisol to inactivation by 11βHSD2.
Dexamethasone has higher afﬁnity for GR than cortisol,
but lower afﬁnity for 11βHSD2. Therefore, our proposed
treatment is a new therapeutic use of an existing, well-
characterised medical treatment—oral dexamethasone
—administered at a low ‘replacement’ dose.
Objectives
The objectives for this trial of oral dexamethasone for
amelioration of HMB, are to: (1) identify the efﬁcacy of
oral dexamethasone, and optimal dose to use; (2)
gather safety data; (3) gather methodological and mech-
anistic insight to allow further development of this or
similar treatment option.
DESIGN AND METHODS
Trial design
A response-adaptive parallel group randomised-
controlled trial was proposed, comparing oral dexa-
methasone (in a range of doses) with placebo treatment,
over three menstrual cycles. This allows, at intervals
across enrolment, adaptation of the investigational treat-
ment allocation probabilities, in response to the
outcome data already collected, so those subsequently
enrolled are more likely to be randomised to doses that
are more informative about the dose–response relation-
ship. This design ensures as robust as possible identiﬁca-
tion of the optimal dose, and maximal study power to
estimate the effect of dexamethasone versus placebo,
assuming treatment for three menstrual cycles. Objective
measurement menstrual blood loss (MBL) was selected
as the outcome, assessing treatment effect in terms of
reduction from baseline in MBL (in the 2nd and 3rd of
these treated cycles). This outcome is well suited to the
adaptive design context since MBL data are available
promptly after treatment, to inform adaptation. An
adaptive design has efﬁciency and ethical advantages.
Efﬁciency gains in terms of sample size required are in
the range 25–40% for a broad spectrum of adaptive
designs.24 This efﬁciency itself constitutes an ethical
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advantage,25 and additionally such a design ensures that
more women are randomised to more effective doses
(see online supplementary ﬁgure).
Development of a Bayesian adaptive design requires
extensive preliminary simulation studies to explore
empirically the performance of candidate designs.24 26
Simulations were performed via fractional factorial
design, covering a range of design options and model
assumptions, including: proportion allocated to placebo
(constant throughout); number of active doses; variance
of the primary outcome (change in MBL from baseline);
shape of the true dexamethasone dose–response curve
for the primary outcome; accrual rate of patients to the
study; and speciﬁc features of the adaptation process,
including the method determining how the randomisa-
tion schedule would be adapted and the frequency with
which this takes place. The simulations allowed the fre-
quentist properties (statistical power and signiﬁcance
level) of candidate adaptive designs to be assessed. The
ﬁnal design selected is one which performs well across a
broad range of scenarios. The adaptive design develop-
ment process will be reported in detail elsewhere (CH
et al, manuscript in preparation).
On the basis of the simulations, the speciﬁc features
of the design selected were: 29% of patients allocated to
placebo throughout; six active doses (0.4–1.8 mg total
daily divided dose of dexamethasone) starting with
equal allocation probability; and ﬁve adaptations, evenly
spaced after 16, 32, 50, 66 and 84 randomisations (see
online supplementary ﬁgure).
Study setting
The participant population will be women reporting
HMB who are referred for management to gynaecology
outpatient departments in NHS Lothian (NHSL),
Scotland, or who attend a community gynaecology clinic
(self-referral or general practitioner (GP) referral).
Additionally, through the Scottish Primary Care Research
Network (SPCRN), women on SPCRN-participating
Lothian GP practice lists who are potentially eligible (ie,
who have codes on their GP practice system suggestive of
HMB), will be sent brief information about the study. Any
of these women who go on to contact the study team will
be invited to be assessed for eligibility at an initial
appointment at an NHSL clinic.
Participants and recruitment
The entry criteria are listed in box 1. Women with symp-
toms of HMB will be given full information about the
study and allowed ample time to read the information
and consider whether they wish to participate. Women
who fulﬁl the ﬁrst four inclusion criteria, do not fulﬁl
any exclusion criteria, and agree to participate, will be
invited to undergo MBL screening to conﬁrm they fulﬁl
the ﬁfth inclusion criterion. Women who decline partici-
pation or are ineligible will be offered routine NHSL
gynaecological care.
Recruitment (to screening) started on January 2014
and can continue to May 2016, with randomisation up
until July 2016.
Intervention
The treatment regimen will be oral dexamethasone or
placebo twice daily, continuing for 5 days, starting on the
seventh day after a luteinising hormone (LH) surge has
been detected by serial urine dipstick testing (day LHu
+7). Thus, for a patient with a regular standard 28-day
cycle, treatment should happen on days 20–24, ending
4 days before the start of the expected next period.
Women who do not wish to carry out serial dipstick testing
will be permitted to participate, but the treatment start
date in each cycle will be estimated ‘pro rata’ on the basis
of the woman’s cycle length documented in previous
screening and treatment cycles. Dipstick testing, where
used, should start early in the follicular phase (about day
6–9 of a 28-day cycle). In the event no LH surge is
detected we will, to avoid missed treatment, specify a
‘latest’ day in the cycle to start treatment, as above.
If a patient is unable to tolerate the trial medication
or develops a serious adverse event, or falls pregnant, or
starts a prohibited medication (see bottom of box 1),
trial medication will be discontinued. The patient will be
followed up for safety and efﬁcacy outcomes. Women
will be reminded by SMS text message when to start
medication. They will also be asked to record study
medication intake and return all unused study medica-
tion. Any medications which are considered necessary
for a patient’s welfare, and which are not ‘prohibited’
(see box 1 ), may be given at the discretion of the senior
clinical investigator. All concomitant medications taken
by the patient during the study from the date of signa-
ture of informed consent until the ﬁnal follow-up visit
will be recorded in the appropriate section of the case
report form.
Outcomes
The primary outcome is reduction in mean MBL, object-
ively measured over the screening and second and third
treatment cycles. However, it has been recommended
that any interventions should aim also to improve
quality-of-life measures.1 Secondary indicators of worth-
while improvement will be collected via the Treatment
Review Questionnaire completed after third treated
cycle, and will address ‘satisfaction’ with treatment (self-
reported ‘lighter’ or ‘much lighter bleeding’, and gener-
ally feeling ‘much better’ during period), improvement
in period pain (‘less’ or ‘much less severe’); and
freedom from unacceptable side effects. We will also
examine change in menstrual diary score for volume of
menstrual period, assessing its reliability and validity as
substitute for change in objectively measured MBL.
Sample size
In trials of medical treatments for HMB it is generally
held that a 25% reduction in MBL would be a
Warner P, et al. BMJ Open 2015;5:e006837. doi:10.1136/bmjopen-2014-006837 3
Open Access
group.bmj.com on January 20, 2015 - Published by http://bmjopen.bmj.com/Downloaded from 
worthwhile improvement27—for example, a 16 mL
reduction for an MBL of 65 mL, a fairly typical MBL
among women with problem of HMB. The trial had
been funded on the expectation that it would be com-
pleted within 3 years, and it was expected that recruit-
ment of and completion by 100–110 participants was
possible within the shorter time frame for recruitment,
to ensure data collection completes about 4 months
before the end of funding. Therefore, all simulations
took 100 as the total study size and thus 4 patients per
month being enrolled. These analyses showed that our
adaptive design is estimated to have statistical power of
93.8%, provided within-patient MBL SD is 18 mL and
maximum mean MBL beneﬁt over placebo is 16 mL.
Patients who withdraw from the study will be replaced,
so to have 100 completing the target, enrolment total is
estimated at 108, based on prior experience.
Adaptive randomisation
The adaptive randomisation will proceed in six phases.
Across the entire study a ﬁxed proportion of patients
(2/7, 29%) will be allocated to placebo, in order to
protect the interpretability of the trial results from any
drift in participant characteristics during the course of
the trial. During phase one (the ﬁrst 16 patients rando-
mised) the remainder of patients will be assigned to one
of the six active dexamethasone daily doses with equal
allocation probability. At the end of the ﬁrst and next
four phases the NDLM (Normal Dynamic Linear
Model) analysis will be run by the unblinded statistician
to ascertain, on the basis of the accumulating MBL
primary outcome data, how the randomisation schedule
should be adapted. (The adaptation timings have been
determined from the pretrial simulations and will take
place after 16, 32, 50, 66 and 84 patients have been
Box 1 Entry criteria
Inclusion criteria
▸ Problem of heavy menstrual bleeding regardless of the presence or not of fibroids
▸ Age 18 years and over
▸ Premenopausal, describing menstrual cycles every 21–42 days
▸ Able to comply with study-related procedures/assessments
▸ Average measured blood loss (MBL), over two screening menstrual cycles, greater/equal to 50 mL
Exclusion criteria
▸ Currently breast feeding
▸ Known coagulation disorder
▸ Renal or liver dysfunction
▸ Ongoing thyroid dysfunction*
▸ Diabetes mellitus
▸ Hereditary galactose intolerance, lactase deficiency or glucose galactose malabsorption†
▸ History or current uterus, cervix, ovarian or breast cancer
▸ Pharmacologically treated moderate/severe hypertension
▸ Psychotic depressive illness
▸ Alcohol or drug abuse
▸ Mental capacity rendering her unable to understand the nature and scope of the study
▸ Participation in treatment phase in any earlier DexFEM work-up study
▸ Currently enrolled in an investigational drug or device study or participated in such a study within the previous 30 days and is still in
exclusion period
▸ Pregnancy possible during the period of study participation‡
▸ Needing to, or intending to, continue taking any of the following prohibited medications§:
– Warfarin
– Sex steroid administration by any route
– Acetylsalicylic acid (aspirin)
– Mefenamic acid
– Antifibrinolytic drugs such as tranexamic acid
– Gonadotropin-releasing hormone agonist and antagonist¶
– Glucocorticoid treatment**
*That is, abnormal thyroid function tests in the 3 months prior to the screening visit.
†Reflecting lactose content of trial medication.
‡Either the woman is planning a pregnancy, or, the woman is at risk of pregnancy and she is not willing to use a non-hormonal method of
contraception (condom, diaphragm) until her participation in the study has ended.
§If a patient has discontinued use she may be considered for inclusion in study (provided otherwise eligible), but only after a sufficient
wash-out period has elapsed. Required wash-out times are shown in online supplementary table.
¶Immediate release or monthly sustained release depot preparation, or 3 or 6 months sustained release depot preparation.
**Any systemic or inhaled treatment, and/or any ‘potent’ topical, or ‘very potent’ topical preparation (see list in online supplementary box I).
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randomised.) During phases 2–6 the allocation probabil-
ity for each active dexamethasone dose will depend on
the amount of new information that a randomisation
would be expected to provide about the underlying
dose–response relationship, based on results collected in
earlier phases. Speciﬁcally, this will be evaluated as the
variance of the primary outcome at the current estimate
of the ED95 (the minimum dose with near-maximal efﬁ-
cacy). The independent data monitoring committee
(DMC) will monitor the progression of the adaptive ran-
domisation to verify that the randomisation schedule is
being adapted appropriately in response to the accumu-
lating MBL data.
Sequence generation
Computer-generated random numbers from the
uniform (0,1) distribution will form the basis for the
allocation sequence. This list of numbers will be gener-
ated by the unblinded programmer at Edinburgh
Clinical Trials Unit (ECTU) in advance and will be
accessed in sequence during the trial to determine the
treatment group for the next randomised participant,
based on the set of treatment allocation probabilities at
the current stage of the adaptive design.
Allocation concealment
Patients will be randomised via a secure website. Based
on the treatment group assigned using the allocation
sequence, a medication code from a predetermined ‘ref-
erence’ list will be automatically added to a printed pre-
scription. (In a Bayesian adaptive design there is no role
for an allocation list, but this ‘reference’ list is needed to
ensure concealment.) This prescription will be dis-
pensed by unblinded pharmacist by referring to the ref-
erence’ list provided in advance by ECTU, and only the
patient number will be included in the treatment
capsule bottle labelling.
Blinding
Unblinded study staff will be the programmer generat-
ing the treatment allocation sequence, the pharmacist
dispensing the drug (or placebo) using the list of medi-
cation codes, the statistician performing the adaptation
analyses and generating the DMC reports, the independ-
ent statistician validating the DMC reports and members
of the independent DMC. Trial participants, care provi-
ders, laboratory staff, research nurses and all other
members of the trial team will remain blinded to the
assigned intervention and regarding adaptations made
to randomisation probabilities.
The study drug manufacturer, Tayside Pharmaceuticalsi
(TP), will manufacture the active and matched placebo
capsules for all arms of the trial using dexamethasone
micronised powder Ph Eur, Lactose Ph Eur and hard
gelatine capsules. (Daily active dose will be split between
morning and evening so the 6 strengths of dexametha-
sone capsules manufactured will be 0.2, 0.4, 0.5, 0.6, 0.75
and 0.9 mg capsules.) The bulk containers will be
labelled to identify the strength of the capsules and these
will be held (out of sight of any of the research team) by
Pharmacy, Royal Inﬁrmary of Edinburgh. Reorder and
resupply will be organised between Pharmacy and TP
without any involvement by the research team.
Participant time line
Figure 1 shows the patient time line, except it omits an
optional clinic appointment that is offered after the ﬁrst
cycle of treatment. From ﬁrst clinic appointment
onwards, any losses to recruitment/retention will revert
to standard National Health Service (NHS) care.
Data collection methods
Table 1 summarises data collection methods and timing.
Questionnaires are outlined in the footnotes to table 1
—they are based on those used in previous
studies.13 28 29 The study doctors and in particular study
nurses will develop excellent rapport with patients to
maximise completeness of data collected. MBL will be
assessed by objective laboratory measurement of col-
lected used sanitary protection, will apply modiﬁed alka-
line haematin method (as previously validated in our
laboratory).28 29 Assessment of ovarian function, via
twice weekly collection of urine samples in third treat-
ment cycle, will allow a check for any effect of dexa-
methasone on ovarian function.30
Monitoring
Data on potential side effects will be collected until
30 days after last study tablet; that is, ‘unusual symptoms’
elicited via study diaries and by nurses/doctors during
contacts with participants. Expected symptoms in this
population are given in online supplementary box II.
The independent DMC convened for the entire
project (including the initial small studies) will, for this
trial, both review proposed adaptations of the random-
isation schedule (see Adaptive randomisation section
above), and will regularly review the safety and efﬁcacy
data. This DMC will be able to recommend termination
of the study in the event of major safety concerns being
identiﬁed.
ANALYSIS
Data management
Trial data accumulation and management is supported
by ECTU. Study data will be stored on a secure SQL
server at ECTU, the trial database being validated in
advance through the use of dummy data and with refer-
ence to a documented validation plan. A detailed data
management plan will also be held on the secure server
at ECTU. Data queries on critical data items will be
iMIA (IMP) 14076) Tayside Pharmaceuticals|Ninewells Hospital|Dundee|
DD1 9SY.
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raised automatically on a monthly basis and circulated to
the study researchers for resolution.
Statistical methods
All analyses will be performed according to the inten-
tion to treat principle. A detailed statistical analysis plan,
taking a Bayesian approach, will be ﬁnalised prior to the
locking of the study database and prior to unblinding of
the treatment codes.
The dose–response curve for change in MBL between
baseline and cycles during randomised treatment will be
analysed using a Bayesian NDLM,26 which is ﬂexible and
requires few assumptions about the shape of the under-
lying dose–response curve. NDLM will yield considerable
efﬁciency gains, since the estimate of efﬁcacy at a given
dose will be informed by that at neighbouring doses.
Mean baseline MBL will be included as a covariate in
the NDLM. The NDLM analysis will determine which of
the doses studied is optimal (in terms of posterior prob-
ability of efﬁcacy). For each dexamethasone dose, a 95%
credible interval will be calculated for the mean differ-
ence in MBL change versus placebo.
Figure 1 Participant time line(s). Notes: #Completes menstrual diary and undertakes menstrual collection for objective MBL
assessment. *Each treatment cycle starts immediately after a menstrual period and finishes at the end of the following period.
Treatment is for 5 days, targeted to start approximately 8 days before the period (GP, general practitioner; HMB, heavy menstrual
bleeding; MBL, menstrual blood loss; mth, month; SPCRN, the Scottish Primary Care Research Network).
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Table 1 Overview of data collection for adaptive trial
Cycle
Screen MBL Treatment
1 2 1 2 3
Data collection By whom? Screen Appt. M Post M Post Pre M Post Pre M Post Pre M Post F-up Appt
Consent Doctor ✓
Clinical history* (CRF) Doctor ✓
Recruitment Questionnaire† Patient ✓
Menstrual collection for MBL‡ Patient ✓ ✓ ✓ ✓ ✓
Menstrual diary record§ (screening) Patient ✓ ✓ ✓
Record of dipstick testing for LH¶ Patient ✓ ✓ ✓
Study diary (treatment phase) Patient
Pregnancy test pretreatment** ✓ ✓ ✓
Record of treatment taken†† ✓ ✓ ✓
Menstrual diary record§ ✓ ✓ ✓
Uplift MBL collection, for assay Doctor/nurse ✓ ✓ ✓ ✓
Check concomitant medications Doctor/nurse ✓ ✓ ✓ ✓ ✓ ✓ ✓
Check for ‘adverse events’ Doctor/nurse ✓ ✓ ✓ ✓ ✓ ✓
Ovarian function (urines)‡‡ Patient ✓ ✓×6 ✓✓ ✓
Safety bloods§§ Doctor/nurse ✓ ✓
Treatment Review Questionnaire¶¶ Patient ✓
*Current health including medication, parity, past treatments etc.
†Detailing HMB problem including duration, associated menstrual symptoms, impact on daily life.
‡See main text.
§To enable an estimate of volume of MBL,31 via recording prospectively sanitary product usage/soaking during period, and to elicit, at the end of each period, subjective assessment of
‘heaviness’, menstrual symptoms compared with past 6 months, and any unusual symptoms.
¶(A) If LH testing (by means of commercially available urine dipsticks), date started and date first positive, and (B) whether or not testing, agreed date to start treatment.
**Except for those who have confirmed with clinical team that they are not ‘at risk’ of pregnancy (eg, sterilised, or not in relevant sexual relationship), date of pregnancy test and confirmation
negative result.
††Date started medication and confirmation of each morning and evening tablet taken.
‡‡Ovarian function will be assessed by requesting in third treatment cycle collection of twice weekly urine aliquots (to be stored in home freezer compartment until MBL uplift) and subsequently
assayed for oestrogen and progesterone metabolites.
§§Undiagnosed (pre) diabetes will be assessed pre-enrolment via plasma glucose and HbA1c, and treatment toxicity will be assessed via plasma glucose, HbA1c, LFTs and urea and
electrolytes.
¶¶Subjective assessment of effect of treatment received, in respect of most recent (treated) menstrual period, including comparison of ‘heaviness’ compared with before entering study.
Appt., appointment; CRF, case report form; F-up, follow-up; HbA1c, glycated haemoglobin; LFTs, liver function tests; LH, luteinising hormone; M, menstrual period; MBL, menstrual blood loss;
post, as soon as period has ended; pre, run up to period.
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Binary or ordinal secondary end points will be ana-
lysed using a generalised dynamic linear model. For
each dexamethasone dose, a 95% credible interval will
be calculated for the OR versus placebo.
No formal stopping rules will be implemented via
interim analysis for futility or efﬁcacy. We anticipate
minimal missing data on key outcomes and therefore do
not plan to use multiple imputation methods to accom-
modate missing data.
ETHICS AND DISSEMINATION
Ethics and governance
The study will be conducted in accordance with the prin-
ciples of the International Conference on Harmonisation
Tripartite Guideline for Good Clinical Practice (ICH
GCP).
All women are provided with detailed information
about the trial prior to deciding to participate, and
provide written informed consent prior to any study-
related procedures. Any woman at risk of pregnancy in a
treatment cycle will be asked to carry out a pregnancy
test as an additional precaution prior to starting the
5 days of study treatment. Patients’ participation is sup-
ported by research nurses highly experienced in men-
strual research.
Participants can withdraw at any time, or the investiga-
tor or care-providing clinician may withdraw the patient
if it is deemed medically necessary. The reasons for with-
drawal/discontinuation and any adverse events will be
recorded. A clear distinction will be made as to whether
the patient is withdrawing solely from trial treatments/
procedures, or whether the patient is also declining
further follow-up, and/or use of data so far collected.
Dissemination
The trial ﬁndings will be made available to participants
on request, and will be disseminated via open-access peer-
reviewed publications, conferences, clinical networks. All
study investigators have a strong and continuing track
record in public engagement, and the University of
Edinburgh, Queen’s Medical Research Institute holds
regular public lectures in the “Let’s talk…. series”.ii
DISCUSSION
The proposed glucocorticoid treatment, dexametha-
sone, is an existing, well-characterised drug, widely used
in clinical care. Glucocorticoids are even used to treat
medical conditions in pregnancy (in ﬁrst trimester for
asthma; rheumatoid arthritis; hyperemesis gravidarum).
This means the safety proﬁle is well-known, and the
exclusion criteria for this research therefore ‘well-
informed’. Furthermore, the modest (short-course)
doses being used are periphysiological. (Typical
equivalent doses of dexamethasone in an acute exacer-
bation of obstructive airways disease, eg, would be
>3 mg/day, or over 66% more than the maximum dose
proposed here.) A further advantage of this phase II
‘new use for an existing drug’ trial, is that if it shows
beneﬁcial effect, ‘drug development’ costs for future use
will be comparatively low.
The rationale for the use of dexamethasone is derived
from mechanistic laboratory studies which suggest a
luteal phase glucocorticoid deﬁciency in the endomet-
rium of women with HMB.20 While participants in the
trial are not individually assessed to have low levels of
endometrial glucocorticoid, it is expected that adminis-
tration of dexamethasone would reverse local endomet-
rial glucocorticoid deﬁciency where this is the case.
A unique feature of adaptive trial design is the time
lag needed between initiation of research funding and
initiating the trial itself, in order to allow the simulation
analyses required to develop the design. In this time we
undertook two small clinical/mechanistic studies, which
involved 15 women in total, and comprised a ﬁrst use of
any modality of glucocorticoid for treatment of HMB.
While these studies were not powered to estimate treat-
ment effect, they enabled: collection of safety data (no
safety concerns were raised and no patient withdrew
during treatment) and mechanistic information (via
repeat before-and-after MRI and endometrial biopsies);
piloting of methods; and a check on some assumptions
that had been fed into the adaptive design simulation
model, for example, within-patient variability in MBL.
Apart from the opportunity for this preliminary work,
adaptive randomisation has notable methodological ben-
eﬁts, in terms of statistical efﬁciency, and ethically.24 25 A
disadvantage is that it is not easy to provide a simple
explanation of adaptive randomisation in the patient
information sheet.
The challenge for this study is recruitment, because a
lot is asked. Participation lasts 6 months, comprising
screening menstrual collections and diary records for two
untreated menstrual periods and then for each of the
three treatment menstrual cycles (1) ovulation testing by
urine dipstick each morning from about day 8, for about
6–10 days depending on cycle length, (2) taking medica-
tion twice a day for 5 days in the mid-luteal phase (exact
start date is calculated from ovulation) and (3) diary
record of the period. In addition, for the second and
third treatment cycles menstrual collection is requested.
At start and ﬁnish safety bloods are taken and in the last
treatment cycle twice-weekly urine collections are
requested to assess ovarian function. It speaks volumes
about the adverse impact of HMB on women’s lives that
patients judge it worthwhile to participate in such a trial.
This also underscores the unmet clinical need for a
medical treatment for HMB that was noted above, par-
ticularly one that is compatible with starting pregnancy.
Therefore, demonstration of efﬁcacy with systemic
administration of dexamethasone has potential beneﬁt
for many women. It will allow further development of
iihttp://www.ed.ac.uk/schools-departments/medicine-vet-medicine/
news-events/all-events/new-treatments.
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this drug as a treatment option, a possible stepping-stone
to more sophisticated/targeted steroid treatment of
HMB.
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